Betahistine: Targeting on Vascular Wall Aging

Authors

  • A.S. Solgalova , Vladislav O. Soldatov, Tat’yana G. Pokrovskaya , O.A. Olesya A. Puchenkova, Sof’ya Ya. Zapesotskaya , Alexandr V. Feitelson , Lev N. Sernov , Vladimir Ya. Provotorov and Volodya G. Pahlevanyan

Keywords:

Betahistine, Endothelial Dysfunction, Atherosclerosis, Histamine, Vertigo.

Abstract

Betahistine are routine drug in neurological practice, which is used to correct vertigo. The clinical efficacy of this drug can
be caused not only by neuro-, but also by endotheliotropic action. In this review, the main information on the potential
mechanisms for the implementation of vasoprotection, including metabolic, NO-ergic, anti-inflammatory and other
components of the action are discussed. Betahistine as histamine receptors type 3 antagonist and histamine receptors type 1
and 2 agonist has a positive effect on cerebral and systemic hemodynamics, and due to anorexigenic action and the ability
to stimulate lipolysis can ameliorate dyslipidemia as well as suppress the synthesis of pro-inflammatory cytokines and
increase the expression of endothelial NO synthase.

Downloads

Published

19191919-August08-2323

Issue

Vol. 46 No. 4 (2019)

Section

Articles